Papp, K <br/><br/>
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.  [electronic resource] 

 -  The British journal of dermatology  Oct 2015 
 - 930-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.13932  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Cutaneous<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Dermatologic Agents--administration & dosage<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Interleukin-23 Subunit p19--immunology<br/>Male<br/>Middle Aged<br/>Psoriasis--drug therapy<br/>Treatment Outcome<br/>Young Adult